Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

In vivo drug discovery for cellular reprogramming to β-cells – towards a future regenerative therapy for diabetes

Objectif

For almost a century we have been able to control diabetes with insulin injections, yet we still have no cure for this prevalent disease. One possible way to cure diabetes is by increasing the number of insulin-producing β-cells in the pancreas. Here, I propose to uncover factors and mechanisms that can increase β-cell numbers through cellular reprogramming. To do so, we will use two complementary discovery approaches—and transition between zebrafish, mouse and human analyses—to perform functional studies with high translational value.

First, we will use a novel drug discovery approach in transgenic zebrafish to identify and characterize small molecules that can promote the reprogramming of various pancreatic cell types to β-cells. Second, we will use single-cell RNA-sequencing to identify genetic signatures of cellular reprogramming to β-cells in humans, and then dissect the function of the identified genes by overexpressing or mutating them in transgenic zebrafish. We will also use lineage-tracing to determine the number and origin of the β-cells the small molecules and genes induce.

Once we identify promising hits in zebrafish, we will treat diabetic mice with small molecules or secreted proteins (targeting the signalling pathways regulated by the hits) and evaluate their effects on glucose control and β-cell mass. We will also test their effects on cellular reprogramming in mice, as indicated by changes in the relative proportion of each hormonal cell type, in the generation of bihormonal cells (insulin+ glucagon+ or insulin+ somatostatin+), and in the number of lineage-traced β-cells. Further, we will determine whether these small molecules or secreted proteins induce reprogramming to β-cells in human islets.

By coupling whole-organism screens with mechanistic and translational studies, we will identify factors and pathways that can enhance cellular reprogramming to β-cells and could thus form the basis of a cure for diabetes.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Régime de financement

ERC-COG - Consolidator Grant

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2017-COG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

UPPSALA UNIVERSITET
Contribution nette de l'UE
€ 200 000,00
Adresse
VON KRAEMERS ALLE 4
751 05 Uppsala
Suède
Région
Östra Sverige Östra Mellansverige Uppsala län
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 200 000,00

Bénéficiaires (2)